United Therapeutics (UTHR) awards 1,220 RSUs to new board member

Rhea-AI Filing Summary

United Therapeutics Corporation disclosed that new director Kevin Tracey received a grant of restricted stock units on January 21, 2026. The award covers 1,220 restricted stock units, each representing the right to receive one share of United Therapeutics common stock after vesting. The units were granted at a price of $0.00 in connection with his appointment to the Board of Directors under the company’s Non-Employee Director Compensation Program.

The award becomes fully vested on the one-year anniversary of the grant date, January 21, 2027. Following this grant, Tracey beneficially owns 1,220 derivative securities in the form of restricted stock units, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tracey Kevin

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	01/21/2026		A(2)		1,220		01/21/2027(1)	(3)	Common Stock	1,220	$0.00	1,220	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. In connection with Kevin Tracey's appointment to the Board of Directors on January 21, 2026, he was awarded restricted stock units in accordance with the Non-Employee Director Compensation Program. Each award becomes fully vested on the one-year anniversary of the grant date.

3. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did United Therapeutics (UTHR) report for Kevin Tracey?

United Therapeutics reported that director Kevin Tracey received a grant of 1,220 restricted stock units on January 21, 2026, in connection with his appointment to the Board of Directors.

How many restricted stock units did Kevin Tracey receive from United Therapeutics (UTHR)?

Kevin Tracey received 1,220 restricted stock units. Each unit represents the right to receive one share of United Therapeutics common stock after vesting.

When do Kevin Tracey’s United Therapeutics (UTHR) restricted stock units vest?

The restricted stock units awarded to Kevin Tracey become fully vested on the one-year anniversary of the grant date, which is January 21, 2027.

What is the exercise or purchase price of Kevin Tracey’s restricted stock units at United Therapeutics (UTHR)?

The restricted stock units were granted with a stated price of $0.00, consistent with typical stock-based compensation awards that convert into common shares upon vesting.

How many United Therapeutics (UTHR) securities does Kevin Tracey beneficially own after this award?

After the reported transaction, Kevin Tracey beneficially owns 1,220 derivative securities in the form of restricted stock units, held directly, according to the filing.

Why did United Therapeutics (UTHR) grant restricted stock units to Kevin Tracey?

The restricted stock units were awarded to Kevin Tracey in connection with his appointment to the Board of Directors on January 21, 2026, under the company’s Non-Employee Director Compensation Program.